[HTML][HTML] Comparison of gut microbiome composition in colonic biopsies, endoscopically-collected and at-home-collected stool samples
Aim The goal of this study is to compare microbiome composition in three different sample
types in women, namely stool brought from home vs. solid stool samples obtained at the …
types in women, namely stool brought from home vs. solid stool samples obtained at the …
NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer
J Doffo, SA Bamopoulos, H Köse… - Proceedings of the …, 2022 - National Acad Sciences
Evasion from drug-induced apoptosis is a crucial mechanism of cancer treatment resistance.
The proapoptotic protein NOXA marks an aggressive pancreatic ductal adenocarcinoma …
The proapoptotic protein NOXA marks an aggressive pancreatic ductal adenocarcinoma …
Copy Number Variations in Pancreatic Cancer: From Biological Significance to Clinical Utility
DJA Oketch, M Giulietti, F Piva - International Journal of Molecular …, 2023 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer,
characterized by high tumor heterogeneity and a poor prognosis. Inter-and intra-tumoral …
characterized by high tumor heterogeneity and a poor prognosis. Inter-and intra-tumoral …
Transportome malfunctions and the hallmarks of pancreatic cancer
Q Ling, H Kalthoff - Transportome Malfunction in the Cancer Spectrum: Ion …, 2020 - Springer
Ion channels and transporters (ICT) play important roles in almost all basic cellular
processes. During last decades, abundant evidences have been provided that ICT (eg …
processes. During last decades, abundant evidences have been provided that ICT (eg …
[HTML][HTML] Combination of RUNX1 inhibitor and gemcitabine mitigates chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis …
C She, C Wu, W Guo, Y Xie, S Li, W Liu, C Xu… - Journal of Experimental …, 2023 - Springer
Background Gemcitabine (GEM)-based chemotherapy is the first-line option for pancreatic
ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its …
ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its …
[HTML][HTML] A novel 20-gene prognostic score in pancreatic adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers. Known risk
factors for this disease are currently insufficient in predicting mortality. In order to better …
factors for this disease are currently insufficient in predicting mortality. In order to better …
Peripheral Tr1 and Foxp3+ Treg as markers of recurrent malignancies in patients with hepato-biliary pancreatic cancers
T Ikemoto, M Shimada, D Ishikawa… - Anticancer …, 2017 - ar.iiarjournals.org
Background/Aim: Recently CD4+ CD49b+ LAG3+ regulatory T (Tr1) cells are reported to be
IL-10 driven, have strong regulatory activities. Thus, this study aimed to investigate whether …
IL-10 driven, have strong regulatory activities. Thus, this study aimed to investigate whether …
Copine 3 as a novel potential drug target for non-small-cell lung carcinoma
KM Sakthivel, VV Prabhu - Journal of Environmental Pathology …, 2017 - dl.begellhouse.com
Cancer originates from uncontrolled cell division in any part of the body. The universal
burden of cancer continues to increase, and its treatment remains ever more challenging …
burden of cancer continues to increase, and its treatment remains ever more challenging …
[PDF][PDF] Identification of vulnerabilities in an aggressive subtype of pancreatic cancer
MJ Doffo - docserv.uni-duesseldorf.de
Evasion from drug-induced apoptosis is one crucial mechanism of treatment resistance in
pancreatic ductal adenocarcinoma (PDAC). In an aggressive PDAC subtype, I identified …
pancreatic ductal adenocarcinoma (PDAC). In an aggressive PDAC subtype, I identified …